Is Egrifta (Tesamorelin) Legal in Alabama?

Federal Legal Framework for Tesamorelin

Tesamorelin is a prescription drug regulated under federal law, not a research chemical or a gray-market compound. The FDA approved Egrifta (tesamorelin 1 mg injection, Theratechnologies) on November 10, 2010, under NDA 022505 for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. 1 A second formulation, Egrifta SV (2 mg/mL), received approval in 2019. 2

Because tesamorelin is not a controlled substance under the federal Controlled Substances Act, prescribers do not need a specific DEA Schedule authorization beyond a standard DEA registration. 3

What FDA Approval Means for Patients

FDA approval means the branded product has passed rigorous Phase III efficacy and safety review. The key tesamorelin trials (LIPO-010 and LIPO-011, combined N=816) showed a mean 18% reduction in visceral adipose tissue (VAT) by MRI after 26 weeks versus placebo (P<0.001), with sustained benefit through 52 weeks. 4 Because the drug is approved and not scheduled, a physician can legally prescribe it to any appropriate patient in any U.S. State, including Alabama.

Tesamorelin and the FDA Bulks List

Tesamorelin does not appear on the FDA's 503A bulk drug substances list that permits pharmacies to compound certain drugs without finished-drug FDA approval. 5 This distinction matters: pharmacies that compound tesamorelin outside the standard 503A or 503B pathway operate in a legally uncertain area. A 503B outsourcing facility registered with FDA can still produce tesamorelin as a compounded drug, provided it meets Current Good Manufacturing Practice standards and the product is not a copy of a commercially available drug. 6 Patients should verify their pharmacy's registration status directly with FDA before accepting compounded tesamorelin.

Alabama State Legal Framework

Alabama does not add a separate state-level schedule or restriction on tesamorelin beyond federal requirements. The Alabama Uniform Controlled Substances Act (Alabama Code Title 20, Chapter 2) lists scheduled substances by category, and tesamorelin does not appear in any Alabama schedule I through V. 7 That means the drug is treated as a standard legend prescription drug under Alabama law.

Alabama Prescribing Authority

Under Alabama Code Section 34-24-70 and the Alabama Medical Practice Act, any physician licensed in Alabama may prescribe legend drugs, including tesamorelin, for any indication the physician deems medically appropriate. 8 Nurse practitioners and physician assistants with collaborative practice agreements can also prescribe legend drugs under Alabama Code Section 34-21-86 and Section 34-24-293, respectively.

Prescribing tesamorelin off-label (for example, for age-related GH decline or body composition in non-HIV patients) is legally permissible in Alabama. Off-label prescribing is a standard medical practice right, not a violation of law, as confirmed by the FDA's own guidance on off-label use. 9 The clinical and ethical responsibility rests with the prescribing physician.

Alabama State Board of Pharmacy Oversight

The Alabama State Board of Pharmacy (ALBOP) oversees all pharmacies dispensing drugs to Alabama patients, whether the pharmacy is located in-state or ships from out of state. Any pharmacy dispensing tesamorelin to an Alabama patient must hold a valid Alabama pharmacy permit or a non-resident pharmacy license issued by ALBOP. 10 Patients can verify a pharmacy's Alabama licensure status through the ALBOP online license verification tool.

Compounding pharmacies that prepare tesamorelin under 503A rules must be state-licensed and comply with USP <797> sterile compounding standards, as enforced by ALBOP and referenced in the FDA guidance on 503A compounding. 11

Approved Indication vs. Off-Label Use in Alabama

Egrifta carries a single FDA-approved indication: reduction of excess abdominal fat in HIV-1-infected adults with lipodystrophy. 1 The approval is based on the LIPO-010 trial (N=412) and LIPO-011 trial (N=404), which documented statistically significant VAT reduction and modest IGF-1 elevation without worsening of glucose metabolism at the 2 mg/day dose. 4

Off-Label Prescribing Realities

Physicians in Alabama sometimes prescribe tesamorelin off-label for conditions such as non-HIV-related visceral obesity, metabolic syndrome, or as a growth-hormone secretagogue in the context of age-related GH deficiency. Off-label use is legal. Whether a specific insurer covers it off-label is a separate question, and most payers in Alabama deny coverage for non-HIV indications because FDA approval does not extend there.

The Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency in Adults states that GH replacement is appropriate in adults with confirmed biochemical GH deficiency from a known pituitary cause, and it does not endorse empirical GH secretagogue therapy in otherwise healthy aging adults. 12 Providers who prescribe tesamorelin off-label in Alabama should document the medical rationale clearly, conduct appropriate testing such as IGF-1 and stimulation testing, and obtain informed consent that includes a discussion of the off-label nature of the therapy.

Pediatric Use

Tesamorelin is not approved for use in patients younger than 18. The FDA label explicitly contraindicates use in pediatric patients. 1 Alabama prescribers should not prescribe Egrifta to minors regardless of indication.

Compounded Tesamorelin: Legal Nuances in Alabama

Compounded tesamorelin sits in a narrower legal corridor than branded Egrifta. The following framework clarifies when compounded tesamorelin is and is not legally defensible for Alabama patients and providers.

503A Retail Compounding Pharmacies

A 503A pharmacy compounds drugs for individual patients based on a valid patient-specific prescription. 13 Because tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) and is not on the FDA's category 1 or category 2 bulk substances list for 503A, a 503A pharmacy compounding tesamorelin operates in a legally uncertain federal space. FDA has taken enforcement action against pharmacies compounding copies of commercially available drugs when a suitable commercial alternative exists. 14 Alabama patients who receive compounded tesamorelin from a 503A pharmacy should ask their provider whether the branded product was considered first.

503B Outsourcing Facilities

A 503B outsourcing facility registered with FDA can produce tesamorelin in bulk without individual patient prescriptions. 6 The facility must comply with cGMP, report adverse events to FDA, and not compound a drug that is a copy of an FDA-approved product unless there is a documented clinical difference (for example, a different concentration or delivery mechanism). Alabama providers prescribing from a 503B facility should confirm the facility's FDA registration is current on the FDA's publicly available outsourcing facility list.

Research-Use Tesamorelin

Tesamorelin sold online for "research use only" without a prescription is not legally dispensable to human patients in Alabama or any other state. The FDA's position is that peptides marketed for "research" that are injected by humans constitute unapproved new drugs. 15 Purchasing such products does not constitute a legal gray area for patients. It constitutes receipt of an unapproved drug, and providers who recommend it may face Alabama Medical Practice Act violations.

How to Get Egrifta (Tesamorelin) in Alabama

Getting a lawful tesamorelin prescription in Alabama involves three steps: clinical evaluation, prescription issuance, and pharmacy dispensing.

Step 1: Clinical Evaluation

A licensed Alabama provider must evaluate the patient, document the clinical indication, order relevant labs (typically IGF-1, fasting glucose, HbA1c, and HIV status if the FDA-approved indication applies), and determine that no contraindications are present. Tesamorelin is contraindicated in patients with active malignancy, disruption of the hypothalamic-pituitary axis from hypophysectomy or radiation, and in pregnancy. 1

Step 2: Telehealth Access in Alabama

Alabama's telehealth statute (Alabama Code Section 34-24-701 through 34-24-708) allows prescribers to establish a valid patient-provider relationship via synchronous audio-visual communication, which is sufficient for prescribing legend drugs. 16 A telehealth prescriber must hold an Alabama medical license. After a proper telehealth evaluation, the provider can issue a tesamorelin prescription that an Alabama-licensed pharmacy can fill by mail.

The Alabama Board of Medical Examiners has confirmed that establishing a patient-physician relationship via telehealth is permissible for non-controlled legend drugs, though providers must document the evaluation as thoroughly as an in-person visit.

Step 3: Dispensing and Insurance

Branded Egrifta is dispensed through specialty pharmacies given its high cost (approximately $4,000, $6,000 per month at retail). Theratechnologies offers a patient assistance program (PAP) for qualified patients. Medicare Part D and Medicaid may cover Egrifta for HIV-positive patients meeting the FDA-approved indication, but coverage is inconsistent across Alabama Medicaid managed care plans.

Patients should contact the Alabama Medicaid Agency or their Part D plan directly to verify prior authorization requirements before starting therapy.

Safety Profile and Monitoring Requirements

Tesamorelin's safety is well-characterized from its Phase III trials and post-marketing data. Providers prescribing to Alabama patients should follow the monitoring parameters established in the FDA-approved labeling and referenced in the Endocrine Society guidelines. 12

Key Adverse Effects

The LIPO-010 and LIPO-011 trials documented the following clinically significant adverse effects at a frequency exceeding placebo by more than 2 percentage points: fluid retention and peripheral edema (6.9% vs. 2.5%), arthralgia (13.3% vs. 7.4%), and injection-site reactions (24.5% vs. 4.2%). 4 IGF-1 levels rose above the age-adjusted normal range in approximately 36% of tesamorelin-treated patients at 26 weeks.

Glucose metabolism requires monitoring. A 52-week extension of the Phase III trial showed no statistically significant worsening of fasting glucose or HbA1c at the group level, but individual patients with pre-existing insulin resistance showed clinically meaningful glucose elevation. 17 Alabama providers should check HbA1c at baseline and at 3 months after initiation.

Monitoring Schedule Recommended by Labeling

Per FDA-approved prescribing information, providers should measure IGF-1 at baseline and approximately 6 weeks after starting therapy. If IGF-1 rises above 3 standard deviations from the mean for age and sex, the dose should be reduced or held. 1 Glucose monitoring every 3 months is prudent for patients with any metabolic risk factors.

Insurance, Cost, and Prior Authorization in Alabama

Most commercial insurers in Alabama require prior authorization for Egrifta and restrict coverage to the FDA-approved indication: HIV-positive adults with confirmed lipodystrophy documented by imaging or clinical examination. Without insurance, retail cost for a 30-day supply of Egrifta 2 mg/mL (Egrifta SV) runs approximately $4,000, $6,000 depending on pharmacy.

Alabama Medicaid covers Egrifta for qualifying HIV patients under its specialty drug formulary, subject to prior authorization. The National Alliance of State and Territorial AIDS Directors publishes guidance on accessing HIV-related medications through state Medicaid programs. 18 Providers should submit clinical documentation of the HIV diagnosis, lipodystrophy findings, and relevant metabolic labs when submitting prior authorization requests.

Theratechnologies' ConnectAID patient support program can assist with prior authorization and co-pay support for commercially insured Alabama patients. Contact information is available at the manufacturer's prescriber portal.

Summary of Legal Pathways for Tesamorelin in Alabama

The clearest legal path to tesamorelin for an Alabama patient runs through a licensed Alabama provider who issues a prescription for branded Egrifta dispensed by an ALBOP-licensed specialty pharmacy. Compounded tesamorelin from an FDA-registered 503B outsourcing facility is a second legal option when the branded product is not appropriate (for example, a documented allergy to an excipient). Research-chemical tesamorelin purchased without a prescription is not legal for human use in Alabama or anywhere in the United States.

Providers should document medical necessity, obtain baseline labs (IGF-1, glucose, HbA1c), and establish a monitoring plan before initiating therapy. Check IGF-1 at 6 weeks and glucose-related labs at 3 months.